Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Restructuring Costs (2022 - 2024)

InMed Pharmaceuticals (INM) has 2 years of Restructuring Costs data on record, last reported at $23282.0 in Q2 2024.

  • For Q2 2024, Restructuring Costs rose 128.69% year-over-year to $23282.0; the TTM value through Jun 2024 reached -$19288.0, changed N/A, while the annual FY2024 figure was $80513.0, 42.73% up from the prior year.
  • Restructuring Costs reached $23282.0 in Q2 2024 per INM's latest filing, up from $10136.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $28441.0 in Q1 2023 and bottomed at -$81147.0 in Q2 2023.